Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

Date publication

décembre 2014

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume , Pr KURTZ Jean-Emmanuel , Dr BENGRINE-LEFEVRE Leila

Tous les auteurs :
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25454413

Résumé

Gastro-intestinal neuroendocrine tumours (GI-NETs) are chemotherapy-resistant tumours. Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF), has shown promising results in several phase II trials of gastro-entero-pancreatic-NETs. We assessed bevacizumab combined with capecitabine, specifically in GI-NET patients.

Mots clés

Administration, Oral, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, Capecitabine, Deoxycytidine, administration & dosage, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Gastrointestinal Neoplasms, drug therapy, Humans, Infusions, Intravenous, Male, Middle Aged, Neuroendocrine Tumors, drug therapy, Treatment Outcome

Référence

Eur. J. Cancer. 2014 Dec;50(18):3107-15